Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Michael J. Morris, MD, discusses key ongoing clinical trials in prostate cancer.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.

Michael J. Morris, MD, discusses updated data from the phase 3 PSMAddition trial supporting lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA-positive mHSPC.

Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.

Michael J. Morris, MD, discusses phase 3 PSMAddition trial data supporting lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA-positive mHSPC.

Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.

Michael J. Morris, MD, discusses the significance of the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.

Hamza Hashmi, MD, outlines considerations for identifying patients with early relapsed/refractory multiple myeloma as candidates for CAR T-cell therapy.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

Lorenzo Falchi, MD, discusses key unmet needs and important next steps for diffuse large B-cell lymphoma research.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Alan L. Ho, MD, PhD, discusses an upcoming phase 3 trial evaluating Oz-V in OPSCC and key aspects of its design.

Christian Grommes, MD, discusses how BTK inhibitors and CAR T-cell therapy fit into the relapsed/refractory primary CNS lymphoma treatment paradigm.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

Michael A. Postow, MD, discusses the current evidence gaps surrounding the management of irAEs in melanoma in the long term.

Michael A. Postow, MD, discusses the importance of multidisciplinary coordination following immune checkpoint inhibitor therapy completion for patients with melanoma.

Michael A. Postow, MD, discusses the significance of understanding how to identify late-onset irAEs and underlying comorbidities unrelated to treatment in melanoma.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

Experts highlight some top hematologic oncology data presented at ASCO 2026, including from key studies in multiple myeloma and diffuse large B-cell lymphoma.

Geoffrey Ku, MD, discusses data from HERIZON-GEA-01 showing zanidatamab plus tislelizumab benefits patients with HER2-positive GEA regardless of PD-L1 status.

The FDA has approved orally disintegrating nilotinib tablets for select patients with chronic myeloid leukemia.

Alan L. Ho, MD, PhD, discusses next steps for the evaluation of Oz-V in OPSCC based on its phase 2 efficacy in patients with treatment-refractory disease.

Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.

Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.

Ginger J. Gardner, MD, FACOG, discusses the importance of elevating the national conversation surrounding gynecologic cancers through collaborative efforts.

Michael J. Mauro, MD, discusses his approach to TKI use in chronic myeloid leukemia and how new FDA approvals inform his practice.

Drs Razavi and Ross note the evolution of ESR1 mutation–directed breast cancer management, including the role of genomic testing at metastatic recurrence.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.